Incyte Corp (NAS:INCY)
$ 57.05 0 (0%) Market Cap: 12.83 Bil Enterprise Value: 9.01 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 86/100

Incyte Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 09:00PM GMT
Release Date Price: $75.56 (-1.61%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter. I'm one of the biotechnology analysts at Goldman Sachs. And we're pleased to have the team from Incyte here with us today. And with us, we have Hervé Hoppenot, CEO of Incyte Pharmaceuticals.

So Hervé, maybe just a big picture question, actually quite a few of them. But as we head into the second half of this year, you have multiple pivotal readouts and NDA submissions on tap. Could you just go over the programs that you're most excited about? What's really coming in the second half? And what do you see as maybe transformative for the company in terms of new developments?

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Okay. No -- I mean the year has been an interesting year in terms of news flow with a number of things happening. Recently, just a few weeks ago, we had the first approval for a JAK inhibitor in GVHD. It's a big milestone because it's a very important disease,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot